|
|
 |
MAY IS VHL AWARENESS MONTH
VHL Family Alliance Launches “Early Detection Empowers Us”,
Advocating Early Detection of VHL Tumors
Media Contact:
Victoria Mechlin
Going Global Communications
+1-949-702-3411
vmechlin@goingglobalcommunications.com
Brookline, MA (April 26, 2004) – This May, VHL Family Alliance
(VHLFA), an international organization of families, friends, physicians,
and researchers, dedicated to improving the diagnosis, treatment, and
quality of life for individuals and families affected by Von Hippel-Lindau
disease, kicks off “Early Detection Empowers Us” with the
goal of advocating the early detection of VHL tumors.
Though most of the public has never even heard of Von Hippel-Lindau (VHL)
disease, VHL is more common than we all think. VHL occurs in every ethnic
group, everywhere in the world, knowing no barriers. It occurs in every
nation, every race and every culture around the world. VHL is a genetic
condition involving the abnormal growth of blood vessels in some parts
of the body that are particularly rich in blood vessels. Over all, about
one person in 32,000 in the world has VHL. About 20% are new mutations,
and 80% are children of parents who themselves had VHL.
“For those with VHL or any challenging disease, unless they have
the full picture, they can’t protect themselves," said Joyce
Graff, Executive Director of the VHL Family Alliance. “They need
to know the nature of the enemy that they are facing. We in the VHL Family
Alliance want to give people a map, turn on the lights and help them learn
how to manage their health.”
In 1982, when Cari Enderle of Huron, Ohio, was
7 years old, her mother died of what was simply diagnosed as a brain tumor.
Doctors had no idea that the tumor could be genetically connected or that
the tumor was a VHL tumor. Then in 2001, after enjoying years of excellent
health, Cari’s blood pressure suddenly began to spike repeatedly
following the arrival of her first daughter. Her doctors soon discovered
that she had a brain tumor. This however was not the cause of the erratic
blood pressure. A month later the cause was found. A large tumor, medically
referred to as a pheochromocytoma, had been growing in her abdomen. Both
tumors were soon extracted in two different operations.
A typical characteristic of VHL is that additional tumors are possible
in the future. Today at age 29, Cari is vigilant about receiving yearly
MRI screenings, CT scans and an eye exam every six months. “Early
detection is key," says Cari. "And once you are diagnosed it
is your responsibility as a patient to go for yearly screenings, to always
communicate with your doctors and to stay informed.”
Dr. Graeme Eisenhofer, PhD, Staff Scientist and Director of the Clinical
Neurochemistry Laboratory, National Institutes of Neurological Disorders
and Stroke at NIH, has worked with VHL patients firsthand. “Pheochromocytomas
are treacherous tumors that can cause dangerous increases in blood pressure
and cardiovascular complications due to the release of certain chemicals.
The tumors can be particularly dangerous during pregnancy, where if not
diagnosed there is a high risk of maternal and fetal mortality,”
said Dr.Eisenhofer. “The tumors are more common in certain hereditary
syndromes, such as VHL, where routine biochemical screening for the tumor
at yearly intervals is recommended. When diagnosed during pregnancy appropriate
precautions can be taken to minimize the risk of maternal and fetal mortality.
Happily, today's biochemical tests are highly sensitive, so as long as
appropriate testing is done, these tumors should not be missed.”
The VHL Family Alliance includes a network of over 27 chapters in the
United States as well as affiliate members in 14 countries around the
world. Evidence has shown that with better diagnostic techniques, imaging
scans (CT and MRI) to watch for tumors before they become a serious problem,
and better and better treatments for dealing with tumors, the outlook
for people with VHL is better each year. Currently, there is no cure for
VHL. The cure is probably 30 years away, and will require a great deal
of work in genetics and in drug development. Meanwhile, the VHL Family
Alliance is working for better management for VHL, for protection from
discrimination in insurance and employment, and to encourage the progress
of genetic research.
The VHL Family Alliance is, an international organization of families,
friends, physicians, and researchers dedicated to improving the diagnosis,
treatment, and quality of life for individuals and families affected by
Von Hippel-Lindau disease. The VHL Family Alliance provides information
for families and physicians about this disorder, and local self-help support
groups for families affected with VHL. Local family support chapters exist
in regions of the U.S. Local chapter meetings are scheduled periodically.
International VHL Support Organizations are established on five continents.
The VHL Family Alliance works with more than 14,000 affected people in
72 countries, with highest growth currently in Spanish-speaking countries.
For more information call 1-800-767-4VHL, or go to www.vhlg.org.
#####
[EDITOR’S NOTE: TO SCHEDULE AN INTERVIEW WITH A VHL SPOKESPERSON,
OR FOR COVERAGE OF INDIVIDUAL CASE STUDIES IN YOUR AREA, PLEASE CONTACT
VICTORIA MECHLIN AT +1 (949) 702-3411 or via email at vmechlin@goingglobalcommunications.com
|